Stock DMP DERMAPHARM HOLDING SE
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Dermapharm Holding SE

Equities

DMP

DE000A2GS5D8

Market Closed - Xetra
Other stock markets
 11:35:01 2024-05-03 am EDT 		5-day change 1st Jan Change
33.5 EUR +4.36% Intraday chart for Dermapharm Holding SE +7.03% -20.88%
Apr. 04 DERMAPHARM : Berenberg keeps its Buy rating ZD
Mar. 28 Dermapharm Holding SE Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The company has a low valuation given the cash flows generated by its activity.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Sales forecast by analysts have been recently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company is in debt and has limited leeway for investment
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
DERMAPHARM HOLDING SE Stock Dermapharm Holding SE
-20.88% 1.94B
B-
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.08% 662B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 546B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.77% 359B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+16.97% 323B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.69% 290B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 234B
B+
NOVARTIS AG Stock Novartis AG
+3.65% 198B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 194B
A+
AMGEN INC. Stock Amgen Inc.
+8.08% 167B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DMP Stock
  4. Ratings Dermapharm Holding SE